| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [2] |
Rinella ME. Nonalcoholic fatty liver disease: a systematic review[J]. JAMA, 2015, 313(22):2263-2273.
|
| [3] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组．非酒精性脂肪性肝病诊疗指南（2010年修订版）[J]．中华肝脏病杂志，2010，18(3):163-166.
|
| [4] |
Bellentani S. The epidemiology of non-alcoholic fatty liver disease[J]. Liver Int, 2017, 37 Suppl 1:81-84.
|
| [5] |
Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1):204-210.
|
| [6] |
Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2016, 61(5):1226-1233.
|
| [7] |
王景骅，虞朝辉．非酒精性脂肪性肝病的诊断研究进展[J]．中华肝脏病杂志，2017，25(2):115-118.
|
| [8] |
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6):1723-1730.
|
| [9] |
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty iver disease-Meat-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatolgy, 2016, 64(1):73-84.
|
| [10] |
Alexander J, Torbenson M, Wu TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-alcoholic liver: a clinical and pathological study[J]. J Gastroenterol Hepatol, 2013, 28(5):848-854.
|
| [11] |
Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2016, 14(1):124-131.
|
| [12] |
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study[J]. Hepatology, 2016, 63(3):827-838.
|
| [13] |
Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease[J]. QJM, 2017, 110(2):73-81.
|
| [14] |
Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis[J]. Hepato Int, 2016, 10(4):632-639.
|
| [15] |
Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma [J]. Metabolism, 2016, 65(8):1151-1160.
|
| [16] |
Tian Y, Ma J, Wang W, et al. Resveratrol supplement inhibited the NF-kappa B inflammation pathway through activating AMPK alpha-SIRT1 pathway in mice with fatty liver[J]. Mol Cell Biochem, 2016, 422(1/2):75-84.
|
| [17] |
Francque S, Verrijken A, Caron S, et al. PPARαgene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2015, 63(1):164-173.
|
| [18] |
Montagner A, Polizzi A, Fouché E, et al. Liver PPARαis crucial for whole-body fatty acid homeostasis and its protective against NAFLD[J]. Gut, 2016, 65(7):1202-1214.
|
| [19] |
Drakaki A, Hatziapostolou M, Polytarchou C, et al. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway[J]. BMC Cancer, 2015(15):542.
|
| [20] |
Hwang HJ, Jung TW, Kim BH, et al. A dipeptidyl peptidase-IV inhibitor improve hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression[J]. Biochem Pharmacol, 2015, 98(1):157-166.
|
| [21] |
Mulder P, Morrison MC, Verschuren L, et al. Reduction of obesity-associated with adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice[J]. Sci Rep, 2016(6):31542.
|
| [22] |
Lei X, Xu JF, Chang RM, et al. JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling[J]. Oncotarget, 2016, 7(26):40266-40284.
|
| [23] |
Seko Y, Sumida Y, Tanaka S, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression[J]. Hepatol Res, 2017，47(11):1083-1092.
|
| [24] |
Ki Kim S, Ueda Y, Hatano E, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Int J Cancer, 2016, 139(11):2512-2518.
|
| [25] |
Lee J, Kim Y, Friso S, et al. Epigenetics in non-alcoholic fatty liver disease[J]. Mol Aspects Med, 2017(54):78-88.
|
| [26] |
Tessitore A, Cicciarelli G, Del Vecchio F, et al. MicroRNA expression analysis in high fat diet-incuced NAFLD-NASH-HCC progression: study on C57BL/6J mice[J]. BMC Cancer, 2016(16):3.
|
| [27] |
李相迁，王玮，贾艳红，等．细胞自噬与非酒精性脂肪性肝病[J]．中华肝脏病杂志，2016，24(8):632-635.
|
| [28] |
Czaja MJ. Function of autophagy in nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2016, 61(5):1304-1313.
|
| [29] |
Ji G, Wang Y, Deng Y, et al. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy[J]. Lipids Health Dis, 2015(14):134.
|
| [30] |
Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature, 2016, 531(7593):253-257.
|
| [31] |
Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma[J]. Cancer Cell, 2016, 30(1):161-175.
|
| [32] |
段娜娜，吴健．哪些非酒精性脂肪性肝炎-肝癌动物模型更具有实用价值?[J]．中华肝脏病杂志，2016，24(3):230-233.
|
| [33] |
罗燕，杨文君，陈建玉，等．非酒精性脂肪性肝炎相关肝细胞癌小鼠模型的建立与鉴定[J]．中华肝脏病杂志，2016，24(4):279-284.
|